Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching
Russia’s biosimilar story is no longer a side plot—it’s becoming the plot.
If you’ve been watching the West’s oncology pipeline and pricing debates, you may have missed the quieter shift happening in Moscow: a growing biosimilar powerhouse building a p…
